XERS News and Press, Xeris Pharmaceuticals Inc. From 11/10/21

Xeris Pharmaceuticals (NASDAQ:XERS): Q3 GAAP EPS of -$0.39. Revenue of $11.03M (+17.3% Y/Y) in-line. Shares +1.02% PM. Press Release As of September 30, 2021, Xeris reported total cash, cash equivalents, and investments of $93.0 million, compared to $133.8 million at December 31, 2020. For ...

Acquisition of Strongbridge Biopharma closed October 5, 2021; integration complete Q3 pro forma net sales of $22.5M: Gvoke® and Keveyis® $11.0M and $11.5M, respectively Gvoke and Keveyis net sales grew 19% compared to Q2 2021 and combined are on track to achi...

Xeris Pharmaceuticals (NASDAQ:XERS) is scheduled to announce Q3 earnings results on Wednesday, November 10th, before market open. The consensus Revenue Estimate is $11.03M (+17.3% Y/Y). Over the last 2 years, XERS has beaten EPS estimates 100% of the time and has beaten revenue estimates 75% ...

ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that the Company will release its third quarter 2021 financial results be...

Shares of Xeris Pharmaceuticals (NASDAQ: XERS) were jumping 7% higher heading into noontime trading Friday after analyst coverage of the specialty biopharma began the day with a buy rating. H.C. Wainwright analyst Oren Livnat also assigned a $4-per-share price target on Xeri...

Xeris Biopharma (XERS +7.2%) is up in morning trading after H.C. Wainwright initiated the company with a buy rating. The firm has a $4 price target (~122% return). Analyst Oren Livnat says that Recorlev (levoketoconazole) for Cushing's syndrome, which has a Jan. 1, 2022 PDUFA date, will do we...

Gainers: G Medical Innovations (NASDAQ:GMVD) +15%, Accuray (NASDAQ:ARAY) +14%, Xeris Biopharma (NASDAQ:XERS) +9%, DURECT (NASDAQ:DRRX) +9%, Ocugen (NASDAQ:OCGN) +7%. Losers: CareDx (NASDAQ:CDNA) -25%, 4D Molecular Therapeutics (NASDAQ:FDMT) -2...

Gainers: IceCure Medical (NASDAQ:ICCM) +15%, Kiromic BioPharma KRBP +12%, Eargo (NASDAQ:EAR) +12%, Context Therapeutics (NASDAQ:CNTX) +11%, Xeris Biopharma XERS +11%. Losers: ERYTECH Pharma ERYP -39%, Eyenovia EYEN -37%, Es...

Remark Holdings (NASDAQ:MARK) +266%. Sonim Technologies (NASDAQ:SONM) +96%. Creatd (NASDAQ:CRTD) +69% announces second NFT drop, includes photographs of former President Donald Trump PAE Incorporated (NASDAQ:PAE) +67% Amentum to buy PAE in an all-cash deal valued at ~$1.9 ...